37 related articles for article (PubMed ID: 1539752)
1. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes.
Coleman RE; Clavin AM; Milhous WK
Am J Trop Med Hyg; 1992 Feb; 46(2):169-82. PubMed ID: 1539752
[TBL] [Abstract][Full Text] [Related]
2. A model of pregnancy-associated malaria for inducing adverse pregnancy outcomes in ICR mouse.
Zhang Y; Liang Z; Xing H; Yu C; Liang J; Xu Q; Song J; He Z
Exp Parasitol; 2024 Feb; 257():108686. PubMed ID: 38158008
[TBL] [Abstract][Full Text] [Related]
3. Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.
Andrade AO; Santos NAC; Bastos AS; Pontual JDC; Araújo JE; Silva AMV; Martinez LN; Lima AA; Aguiar ACC; G Teles CB; Medeiros JF; Pereira DB; Vinetz JM; Gazzinelli RT; Araújo MS
PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011425. PubMed ID: 37327209
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Barber BE; Abd-Rahman AN; Webster R; Potter AJ; Llewellyn S; Marquart L; Sahai N; Leelasena I; Birrell GW; Edstein MD; Shanks GD; Wesche D; Moehrle JJ; McCarthy JS
Clin Infect Dis; 2023 Jun; 76(11):1919-1927. PubMed ID: 36795050
[TBL] [Abstract][Full Text] [Related]
5. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine and G6PD: a primer for clinicians.
Chu CS; Freedman DO
J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30941413
[TBL] [Abstract][Full Text] [Related]
7. Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.
Melariri P; Kalombo L; Nkuna P; Dube A; Hayeshi R; Ogutu B; Gibhard L; deKock C; Smith P; Wiesner L; Swai H
Int J Nanomedicine; 2015; 10():1493-503. PubMed ID: 25759576
[TBL] [Abstract][Full Text] [Related]
8. Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.
Upton LM; Brock PM; Churcher TS; Ghani AC; Gething PW; Delves MJ; Sala KA; Leroy D; Sinden RE; Blagborough AM
Antimicrob Agents Chemother; 2015 Jan; 59(1):490-7. PubMed ID: 25385107
[TBL] [Abstract][Full Text] [Related]
9. Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination.
Abdul-Ghani R; Beier JC
Parasitol Res; 2014 Oct; 113(10):3535-46. PubMed ID: 25185662
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.
Green JA; Patel AK; Patel BR; Hussaini A; Harrell EJ; McDonald MJ; Carter N; Mohamed K; Duparc S; Miller AK
J Clin Pharmacol; 2014 Sep; 54(9):995-1005. PubMed ID: 24700490
[TBL] [Abstract][Full Text] [Related]
12. Chemical signatures and new drug targets for gametocytocidal drug development.
Sun W; Tanaka TQ; Magle CT; Huang W; Southall N; Huang R; Dehdashti SJ; McKew JC; Williamson KC; Zheng W
Sci Rep; 2014 Jan; 4():3743. PubMed ID: 24434750
[TBL] [Abstract][Full Text] [Related]
13. Using genetic methods to define the targets of compounds with antimalarial activity.
Flannery EL; Fidock DA; Winzeler EA
J Med Chem; 2013 Oct; 56(20):7761-71. PubMed ID: 23927658
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
Miller AK; Harrell E; Ye L; Baptiste-Brown S; Kleim JP; Ohrt C; Duparc S; Möhrle JJ; Webster A; Stinnett S; Hughes A; Griffith S; Beelen AP
Br J Clin Pharmacol; 2013 Dec; 76(6):858-67. PubMed ID: 23701202
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.
Adjalley SH; Johnston GL; Li T; Eastman RT; Ekland EH; Eappen AG; Richman A; Sim BK; Lee MC; Hoffman SL; Fidock DA
Proc Natl Acad Sci U S A; 2011 Nov; 108(47):E1214-23. PubMed ID: 22042867
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.
Bousema T; Drakeley C
Clin Microbiol Rev; 2011 Apr; 24(2):377-410. PubMed ID: 21482730
[TBL] [Abstract][Full Text] [Related]
17. Resistance to therapies for infection by Plasmodium vivax.
Baird JK
Clin Microbiol Rev; 2009 Jul; 22(3):508-34. PubMed ID: 19597012
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti.
Pradines B; Mamfoumbi MM; Tall A; Sokhna C; Koeck JL; Fusai T; Mosnier J; Czarnecki E; Spiegel A; Trape JF; Kombila M; Rogier C
Antimicrob Agents Chemother; 2006 Sep; 50(9):3225-6. PubMed ID: 16940138
[No Abstract] [Full Text] [Related]
19. Transmission-blocking activities of quinine, primaquine, and artesunate.
Chotivanich K; Sattabongkot J; Udomsangpetch R; Looareesuwan S; Day NP; Coleman RE; White NJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):1927-30. PubMed ID: 16723547
[TBL] [Abstract][Full Text] [Related]
20. The evolution of tafenoquine--antimalarial for a new millennium?
Peters W
J R Soc Med; 1999 Jul; 92(7):345-52. PubMed ID: 10615272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
